everyone, today. Thanks, thank joining Bruce, you, and for us
thought in best-in-class I of company. with drugs. we've to our a evolution a progress X leukemias XXXX the objective morning, global first this and integrated we the patients all the volunteers, minutes made briefly ambitious few AD, on in and and it exceptionally first degrader reflecting our with means which importance what build solid believe with for would medicines fully investigational time year was lymphomas, XXXX for I patients important spend indications, Kymera's immune-inflammatory is healthy tumors those with HS for a
company is clinic. into modality. accomplishment preclinical three pioneering PK/PD seen substantial a of safety that translation new a a is across our now We've for This the programs, strong and
the first with clinical of degrader a versus benefits have small we Phase indications and a a degrader I time, our heterobifunctional clinical of the differential addition, proof-of-concept KT-XXX molecule first data. In inhibitor seen, in immune-inflammatory of for
the of year late clinical expectations. cohort the IRAKX degrader exceeded of that our from we patient Phase KT-XXX data I shared fact, last study In
And clinical volunteer we XXXX. We replicate The the early an were with but patients in to and trial in in body the and that effect. able shares of the And demonstrated molecule and activity reported reasons on II signs lastly, think healthy effectively encouraging pathway a and molecule. no in well produce and serious patients. disease-relevant dragging strong impact encouraging including profile HS clinical was our represent inflammatory the we QT initiate generally We course, of AD the tolerated partner, of enthusiasm that some studies skin. portion potential really IRAKX we of of to believe HS Phase in Sanofi, the events, able adverse resolution of degrader biomarkers were our PK/PD to in will their AD
of inflammatory a more standard can program. the role obviously, regarding little for wide Jared was an conditions. believe call a this broad steps we in bit KT-XXX, on variety this But a in milestone care molecule will that the next a and of raising share for unique have the important
studies by other partner, diseases. patient and Assuming could profile as encouraging AD followed believe a the initiate and studies consistent our small in medicine molecule's be a for tested to potentially profile best-in-class with Sanofi, and safety emerging initially additional we're populations, remained across larger efficacy HS, in this the we molecule several year, excited KT-XXX we And indications.
tumors both dose-limiting without we disclosed their clinical knock toxicity. I targets programs, X and overshadowed currently encouraging results, IRAKIMiD the somewhat stage our made STATX our pharmacodynamic Both activity phases programs degrader in any the blood and the escalation dose of studies. in of and December, oncology perhaps KT-XXX, clinical degrader. progress KT-XXX by are in While KT-XXX, Phase down we the In first
to data of Importantly, work preclinical to into developing and our fidelity and our highlighting promising these later validating approach year molecules. when will activity, further active we've and ability hope our to we we data Phase from reach our the replicate this initial of trials show targeted PK/PD populations. clinical clinical seen I share that levels position translation discovering settings, profiles from us expected patient dose high-value in particularly safety The these
in targeted our of therapeutic choices, have harness approach over mind, represent need disease target in believe represent many areas transformative made a and of strategies, This together, intentional in that X to the in cutting-edge and selection area With the in patient platform our we strategy. by degradation company focus, markets years Taken where including differentiated which on a or approach and goal to best principles led disease protein very we of and corporate patients' us we the targets need the approach protein meaningfully with key ago target or these believe only R&D investments design started is potential areas, significant remained outcome. areas that we this elucidate a degradation results significant improve address desired clear has lives. unchanged, biology validation conjunction to strategy Since strategy. now, of can't focus be the clinical to way of traditional funding addressed medicines
into from capabilities the we company, of high-value December to medicines. building resulting platform belief our preclinical PK, the the in to you and ability have patients, data I past programs and years, totality we -- we've our X and translate investments X validated reflect understanding important work a the in creating on new share the become our and made you as potential that and have progress the biology, design proven years over of disease that the almost models molecular hope in presented high-quality PD that safety
cleared degrader, in close I had cancers. FDA our to year, intact remains of pXX, is XX% on X our will of tumor more KT-XXX shortly. share I At MDMX to programs for end are for Before the IND regulator suppressor KT-XXX. most beginning Jared that the hand just crucial for which we over a the that just plans common MDMX of the the the Jared, should I call announced discussed mention Kymera. also last the
We ways also enhanced programs indications harness by biology pipeline drug the at early in year, engine. our computational immunology research to advances disease allowed earlier evidence have that innovative us both stage productivity hinted the of These of our other fueled of part discovery and in develop and oncology have to further several in TPD. been new understanding tools our in
expand on In the this addition year and as platform, in of are share we applicability therapeutic leadership heterobifunctional groups hope discovery to later the well. more our also to molecular novel degraders, that the of in identifying we
legal recently Ellen our scientific Along and the Chiniara, Officer resources us to where Ellen work with Chief overseeing Legal have she with serve company a progress, as appointed people member companies clinical Alexion discovery and our extensive and at Secretary, will we we ensure ranging as build experience joins Corporate sustainably. from We to that leadership commercialization. phase from our Pharmaceuticals biopharmaceutical key team. activities of through
responsibilities This Therapeutics. Mosher joined us medicine, as Senior She Novartis, increasing Vertex Millennium. and Rebecca translational from and Translational research at positions month, our of molecular pathology Mersana held of translational Vice previously in President Medicine
She Williams was Biology Head important Juliet will our strategy as more previously also selection profoundly of roles Novartis, Kymera to next our of as contributed recently degrader development at experience, discovery Millennium has roles Sanofi, therapies and Curis. appointed including our to Kymera's than drug and and leadership help of we navigate bring target development to patients. years work revolutionary These Head Research. stage XX We efforts. of new Juliet drug
an we expected Finally, very half read in IRAKX financial ended proof-of-concept approximately the us of into II the study, Phase in runway our the to second continue importantly, programs, our with year will XXXX, us an for in platform clinical and oncology position out which million pipeline a X cash, allow invest solid $XXX programs. and initial discovery clinical proof-of-concept allow to to
in will I handing recent key available. concluding to progress for covering and our Q&A then Jared? financial with programs before session Jared, finish be goals will update. including more call now for the each cover myself operator our disclosed call Bruce the over our returning a of before remarks, XXXX for a Jared to which the some in for will Bruce details
